ibrutinib
janssen,abbvie
['ibru', 'cll']
 insightful update on a well-conducted trial cll12
ibrutinib v placebo for asymptomatic cll no overall survival difference
excess aes &amp; gr 5 aes from ibrutinib soc remains watch &amp; wait
#17icml 
haematology registrar | @harvardmed fellow @PORTAL_research | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer | SoMe Ed @BrJHaem